Beeline Medicines

Beeline Medicines is a clinical-stage biotechnology company headquartered in Stamford, Connecticut, with operations in Boston, Massachusetts. Founded in July 2025 and publicly debuted in April 2026, the company is focused on developing precision therapies for autoimmune and inflammatory diseases, targeting the underlying drivers of immune dysfuncti... on rather than symptom management alone. Its pipeline consists of five programs in-licensed from Bristol Myers Squibb, including afimetoran, a once-daily oral small-molecule TLR7/TLR8 inhibitor in Phase 2 development for lupus, as well as candidates in development for atopic dermatitis, plaque psoriasis, and other immune-mediated conditions. The company also has two preclinical next-generation biologics targeting the IL-10 and IL-18 pathways advancing toward first-in-human studies. Beeline Medicines is backed by a $300 million Series A financing led by Bain Capital and is led by a management team with prior experience at SpringWorks Therapeutics, Robinhood, and other life sciences organizations.Read More